Statins induce apoptosis in rat and human myotube cultures by inhibiting protein geranylgeranylation but not ubiquinone.

Statins are widely used to treat lipid disorders. These drugs are safe and well tolerated; however, in <1% of patients, myopathy and/or rhabdomyolysis can develop. To better understand the mechanism of statin-induced myopathy, we examined the ability of structurally distinct statins to induce apoptosis in an optimized rat myotube model. Compound A (a lactone) and Cerivastatin (an open acid) induced apoptosis, as measured by TUNEL and active caspase 3 staining, in a concentration- and time-dependent manner. In contrast, an epimer of Compound A (Compound B) exhibited a much weaker apoptotic response. Statin-induced apoptosis was completely prevented by mevalonate or geranylgeraniol, but not by farnesol. Zaragozic acid A, a squalene synthase inhibitor, caused no apoptosis on its own and had no effect on Compound-A-induced myotoxicity, suggesting the apoptosis was not a result of cholesterol synthesis inhibition. The geranylgeranyl transferase inhibitors GGTI-2133 and GGTI-2147 caused apoptosis in myotubes; the farnesyl transferase inhibitor FTI-277 exhibited a much weaker effect. In addition, the prenylation of rap1a, a geranylgeranylated protein, was inhibited by Compound A in myotubes at concentrations that induced apoptosis. A similar statin-induced apoptosis profile was seen in human myotube cultures but primary rat hepatocytes were about 200-fold more resistant to statin-induced apoptosis. Although the statin-induced hepatotoxicity could be attenuated with mevalonate, no effect was found with either geranylgeraniol or farnesol. In studies assessing ubiquinone levels after statin treatment in rat and human myotubes, there was no correlation between ubiquinone levels and apoptosis. Taken together, these observations suggest that statins cause apoptosis in myotube cultures in part by inhibiting the geranylgeranylation of proteins, but not by suppressing ubiquinone concentration. Furthermore, the data from primary hepatocytes suggests a cell-type differential sensitivity to statin-induced toxicity.

[1]  R. Laaksonen,et al.  Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short‐term simvastatin treatment in humans , 1995, Clinical pharmacology and therapeutics.

[2]  M. Moskowitz,et al.  Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[3]  M. Kitagawa,et al.  Geranylgeranyl-Pyrophosphate, an Isoprenoid of Mevalonate Cascade, Is a Critical Compound for Rat Primary Cultured Cortical Neurons to Protect the Cell Death Induced by 3-Hydroxy-3-Methylglutaryl-CoA Reductase Inhibition , 2000, The Journal of Neuroscience.

[4]  H. Yasumitsu,et al.  Serum-free culture conditions for analysis of secretory proteinases during myogenic differentiation of mouse C2C12 myoblasts. , 1999, Analytical biochemistry.

[5]  H. Nakagawa,et al.  HMG‐CoA reductase inhibitor‐induced L6 myoblast cell death: involvement of the phosphatidylinositol 3‐kinase pathway , 1998, FEBS letters.

[6]  C. Chou,et al.  In Vitro Apoptosis in the Human Hepatoma Cell Line Induced by Transforming Growth Factor β1 , 1992 .

[7]  Z. Ao,et al.  Upregulated expression of human membrane type-5 matrix metalloproteinase in kidneys from diabetic patients. , 2001, American journal of physiology. Renal physiology.

[8]  T. Ohm,et al.  Blockade of HMG‐CoA reductase activity causes changes in microtubule‐stabilizing protein tau via suppression of geranylgeranylpyrophosphate formation: implications for Alzheimer's disease , 2003, The European journal of neuroscience.

[9]  R G Shulman,et al.  The "glycogen shunt" in exercising muscle: A role for glycogen in muscle energetics and fatigue. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[10]  G. Rodan,et al.  Bisphosphonates Act Directly on the Osteoclast to Induce Caspase Cleavage of Mst1 Kinase during Apoptosis , 1999, The Journal of Biological Chemistry.

[11]  A. Vasudevan,et al.  Potent, highly selective, and non-thiol inhibitors of protein geranylgeranyltransferase-I. , 1999, Journal of medicinal chemistry.

[12]  J. Veerkamp,et al.  Effects of HMG-CoA reductase inhibitors on growth and differentiation of cultured rat skeletal muscle cells. , 1996, Biochimica et biophysica acta.

[13]  A. Álvarez,et al.  Lovastatin Induces Apoptosis of Spontaneously Immortalized Rat Brain Neuroblasts: Involvement of Nonsterol Isoprenoid Biosynthesis Inhibition , 2001, Molecular and Cellular Neuroscience.

[14]  S. Matzno,et al.  Inhibition of cholesterol biosynthesis by squalene epoxidase inhibitor avoids apoptotic cell death in L6 myoblasts. , 1997, Journal of lipid research.

[15]  C. Pinset,et al.  Manipulation of medium conditions and differentiation in the rat myogenic cell line L6. , 1984, Developmental biology.

[16]  B. Halmos,et al.  Mechanism of lovastatin-induced apoptosis in intestinal epithelial cells. , 2002, Carcinogenesis.

[17]  J. Myers,et al.  Up-regulation of type XIX collagen in rhabdomyosarcoma cells accompanies myogenic differentiation. , 1999, Experimental cell research.

[18]  G. Rodan,et al.  Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation. , 2001, Molecular pharmacology.

[19]  I. Shiojima,et al.  The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. , 2000, Nature Medicine.

[20]  S. Sebti,et al.  Disruption of Oncogenic K-Ras4B Processing and Signaling by a Potent Geranylgeranyltransferase I Inhibitor(*) , 1995, The Journal of Biological Chemistry.

[21]  M. Minden,et al.  Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells , 2001, Leukemia.

[22]  V. Funanage,et al.  Entactin promotes adhesion and long‐term maintenance of cultured regenerated skeletal myotubes , 1992, Journal of cellular physiology.

[23]  A M Zeiher,et al.  HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. , 2001, The Journal of clinical investigation.

[24]  G. Bills,et al.  Discovery, biosynthesis, and mechanism of action of the zaragozic acids: potent inhibitors of squalene synthase. , 1995, Annual Review of Microbiology.

[25]  W. H. Schaefer,et al.  Evaluation of ubiquinone concentration and mitochondrial function relative to cerivastatin-induced skeletal myopathy in rats. , 2004, Toxicology and applied pharmacology.

[26]  M. Minden,et al.  Cerivastatin triggers tumor-specific apoptosis with higher efficacy than lovastatin. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  J. Beck,et al.  Enzyme immunoassays with special reference to ELISA techniques. , 1978, Journal of clinical pathology.

[28]  R. Gregg,et al.  In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes. , 1995, Toxicology and applied pharmacology.

[29]  A. Alberts,et al.  The toxicity of a fluorinated-biphenyl HMG-CoA reductase inhibitor in beagle dogs. , 1991, Fundamental and applied toxicology : official journal of the Society of Toxicology.

[30]  I. Grierson,et al.  Apoptosis in multinucleated skeletal muscle myotubes. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[31]  D. Carey,et al.  Extracellular matrix is required for skeletal muscle differentiation but not myogenin expression , 1996, Journal of cellular biochemistry.

[32]  Wen-Sen Lee,et al.  Lovastatin induces apoptosis of anaplastic thyroid cancer cells via inhibition of protein geranylgeranylation and de novo protein synthesis. , 2003, Endocrinology.

[33]  R. Gregg,et al.  Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro. , 1997, Toxicology and applied pharmacology.

[34]  N. Thornberry,et al.  The Caspase-3 Precursor Has a Cytosolic and Mitochondrial Distribution: Implications for Apoptotic Signaling , 1998, The Journal of cell biology.

[35]  P. Kiener,et al.  Inhibitors of HMG-CoA reductase sensitize human smooth muscle cells to Fas-ligand and cytokine-induced cell death. , 2000, Atherosclerosis.

[36]  R. Schwartz,et al.  TNF‐α regulates early differentiation of C2C12 myoblasts in an autocrine fashion , 2001 .

[37]  M. Sandri.  Apoptotic signaling in skeletal muscle fibers during atrophy , 2002, Current opinion in clinical nutrition and metabolic care.

[38]  T. Skopek,et al.  Use of real‐time gene‐specific polymerase chain reaction to measure RNA expression of three family members of rat cytochrome P450 4A , 2001, Journal of biochemical and molecular toxicology.

[39]  W. Steinke,et al.  Preclinical review of cerivastatin sodium--a step forward in HMG-CoA reductase inhibition. , 1998, Atherosclerosis.

[40]  S. Grossman,et al.  HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporine A interaction and mechanism studies. , 1991, The Journal of pharmacology and experimental therapeutics.

[41]  B. Roth,et al.  Hepatic and nonhepatic sterol synthesis and tissue distribution following administration of a liver selective HMG-CoA reductase inhibitor, CI-981: comparison with selected HMG-CoA reductase inhibitors. , 1992, Biochimica et biophysica acta.

[42]  J. Kraniak,et al.  Regulation of rat hepatic cytochrome P450 expression by sterol biosynthesis inhibition: inhibitors of squalene synthase are potent inducers of CYP2B expression in primary cultured rat hepatocytes and rat liver. , 1998, Molecular pharmacology.

[43]  J. Reijneveld,et al.  Differential Effects of 3-Hydroxy-3-methylglutaryl-Coenzyme A Reductase Inhibitors on the Development of Myopathy in Young Rats , 1996, Pediatric Research.

[44]  J. Mönkkönen,et al.  Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. , 1999, Molecular pharmacology.

[45]  M. Leist,et al.  Murine hepatocyte apoptosis induced in vitro and in vivo by TNF-alpha requires transcriptional arrest. , 1994, Journal of immunology.

[46]  W. W. Nichols,et al.  Rapid DNA degradation in primary rat hepatocytes treated with diverse cytotoxic chemicals: Analysis by pulsed field gel electrophoresis and implications for alkaline elution assays , 1994, Environmental and molecular mutagenesis.

[47]  Christian Hodel,et al.  Myopathy and rhabdomyolysis with lipid-lowering drugs. , 2002, Toxicology letters.

[48]  G. Wesolowski,et al.  Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[49]  M. Sandri,et al.  Apoptosis of skeletal muscles during development and disease. , 1999, The international journal of biochemistry & cell biology.

[50]  P. Richardson,et al.  Lovastatin decreases coenzyme Q levels in humans. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[51]  F. Ramsey,et al.  The statistical sleuth : a course in methods of data analysis , 2002 .

[52]  I. Hamilton-Craig,et al.  Statin‐associated myopathy , 2001, The Medical journal of Australia.

[53]  J. Dichgans,et al.  Lovastatin and phenylacetate induce apoptosis, but not differentiation, in human malignant glioma cells , 2001, Acta Neuropathologica.

[54]  C. Weill,et al.  Matrigel enhances myotube development in a serum-free defined medium , 1992, International Journal of Developmental Neuroscience.

[55]  C. Pinset,et al.  Induction of myogenic differentiation in serum-free medium does not require DNA synthesis. , 1985, Developmental biology.

[56]  C. Leeuwenburgh,et al.  Apoptosis in skeletal muscle with aging. , 2002, American journal of physiology. Regulatory, integrative and comparative physiology.

[57]  D. Andres,et al.  Novel salvage pathway utilizing farnesol and geranylgeraniol for protein isoprenylation. , 1997, Biochemical and biophysical research communications.